The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.

Subjects

Subjects :

Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents pharmacology
Antineoplastic Agents therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Genetic Therapy adverse effects
Genetic Therapy methods
Humans
Immunomodulation drug effects
Immunotherapy adverse effects
Melanoma genetics
Melanoma pathology
Neoplasm Staging
Oncolytic Virotherapy adverse effects
Oncolytic Viruses classification
Oncolytic Viruses genetics
Transgenes
Treatment Outcome
Immunotherapy methods
Melanoma immunology
Melanoma therapy
Oncolytic Virotherapy methods

Details

Language :

English

ISSN :

1543-0790

Volume :

14

Issue :

8

Database :

MEDLINE

Journal :

Clinical advances in hematology & oncology : H&O

Accession number :

27487099